Reaction
Dysmetria reporting signals
As of the last recalculation, Dysmetria appears in 595 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is SIPONIMOD (PRR 64.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Siponimod | 16 | 64.4 | 64.6 |
| Metronidazole Topical | 62 | 50.7 | 50.8 |
| Metronidazole | 71 | 44.0 | 44.1 |
| Phenytoin | 20 | 34.7 | 34.7 |
| Valproic Acid | 25 | 28.9 | 28.9 |
| Moxifloxacin | 11 | 27.8 | 27.8 |
| Valproate Sodium | 16 | 27.8 | 27.8 |
| Vigabatrin | 11 | 26.9 | 26.9 |
| Lamotirigine | 48 | 25.4 | 25.4 |
| Lamotrigine Extended-Release | 48 | 25.4 | 25.4 |
| Lamotrigine Chewable Dispersible | 48 | 25.4 | 25.4 |
| Blinatumomab | 7 | 23.7 | 23.8 |
| Ceftriaxone | 21 | 23.2 | 23.2 |
| Thiotepa | 6 | 22.2 | 22.2 |
| Zonisamide | 9 | 21.6 | 21.6 |
| Insulin Degludec | 14 | 21.3 | 21.4 |
| Ceftriaxone Sodium | 22 | 20.8 | 20.8 |
| Fingolimod Hcl | 36 | 15.4 | 15.4 |
| Ranolazine | 4 | 13.5 | 13.5 |
| Asenapine Maleate | 3 | 12.2 | 12.2 |
| Dalfampridine | 24 | 12.2 | 12.2 |
| Ocrelizumab | 20 | 11.6 | 11.6 |
| Axicabtagene Ciloleucel | 3 | 10.7 | 10.7 |
| Paliperidone | 7 | 10.6 | 10.6 |